PTC Therapeutics Financials

PTCT Stock  USD 29.44  1.48  5.29%   
Based on the key indicators related to PTC Therapeutics' liquidity, profitability, solvency, and operating efficiency, PTC Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, PTC Therapeutics' Total Liabilities is comparatively stable compared to the past year. Property Plant Equipment is likely to gain to about 87.7 M in 2024, whereas Short Term Investments are likely to drop slightly above 281.6 M in 2024. Key indicators impacting PTC Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio1.922.0206
Notably Down
Pretty Stable
The financial analysis of PTC Therapeutics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for PTC Therapeutics includes many different criteria found on its balance sheet. For example, investors should never minimize PTC Therapeutics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor PTC Therapeutics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in PTC Therapeutics.

Net Income

(595.27 Million)

With this module, you can analyze PTC financials for your investing period. You should be able to track the changes in PTC Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past PTC Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of PTC Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in PTC Therapeutics' assets may result in an increase in income on the income statement.
Evaluating PTC Therapeutics' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of PTC Therapeutics' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the PTC Therapeutics' relative financial performance

Chance Of Distress

Less than 32

 
100  
 
Zero
Below Average
PTC Therapeutics has less than 32 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for PTC Therapeutics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, PTC Therapeutics' odds of distress score SHOULD NOT be confused with the real chance of PTC Therapeutics filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as PTC is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include PTC Therapeutics' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in PTC Therapeutics' official financial statements usually reflect PTC Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of PTC Therapeutics. For example, before you start analyzing numbers published by PTC accountants, it's critical to develop an understanding of what PTC Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of PTC Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PTC Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in PTC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PTC Therapeutics. Please utilize our Beneish M Score to check the likelihood of PTC Therapeutics' management manipulating its earnings.

PTC Therapeutics Company Summary

PTC Therapeutics competes with Agilent Technologies, and Mediwound. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Ptc Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001070081
ISINUS69366J2006
CUSIP69366J200
RegionNorth America
LocationNew Jersey; U.S.A
Business Address100 Corporate Court,
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.ptcbio.com
Phone908 222 7000
CurrencyUSD - US Dollar
You should never invest in PTC Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of PTC Stock, because this is throwing your money away. Analyzing the key information contained in PTC Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

PTC Therapeutics Key Financial Ratios

Generally speaking, PTC Therapeutics' financial ratios allow both analysts and investors to convert raw data from PTC Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of PTC Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that PTC Therapeutics reports annually and quarterly.

PTC Therapeutics Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets1.6B2.2B1.9B1.7B1.9B2.0B
Other Current Liab197.3M245.8M60.8M365.2M580.3M609.3M
Other Liab490.7M1.0B1.1B269.5M309.9M263.2M
Accounts Payable10.3M18.7M23.0M27.3M6.0M9.9M
Cash686.6M208.8M773.4M410.7M594.0M623.7M
Other Assets16.4M60.6M46.5M33.4M38.4M40.3M
Long Term Debt293.9M309.1M281.9M571.7M1.9B2.0B
Other Current Assets17.9M39.5M(126.3M)105.7M150.3M157.8M
Total Liab1.0B1.7B1.9B2.1B2.7B2.9B
Net Debt(372.7M)211.6M(341.9M)292.9M(179.0M)(187.9M)
Retained Earnings(1.2B)(1.6B)(2.1B)(2.7B)(3.3B)(3.1B)
Net Receivables55.5M69.9M110.5M155.6M161.0M169.1M
Total Current Assets779.3M1.2B773.4M693.8M1.2B1.3B
Short Term Debt20M8.7M159.8M12.4M16.0M15.2M
Common Stock62K70K71K72K75K48.1K
Net Tangible Assets(198.5M)(315.7M)(805.7M)(1.1B)(1.0B)(970.7M)
Capital Surpluse1.8B2.2B2.1B2.3B2.7B1.6B
Inventory19.3M18.7M15.9M21.8M30.6M32.1M

PTC Therapeutics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what PTC Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense12.5M56.4M86.0M90.9M129.2M135.6M
Total Revenue307.0M380.8M538.6M698.8M937.8M984.7M
Research Development257.5M477.6M540.7M651.5M666.6M699.9M
Cost Of Revenue12.1M18.9M32.3M44.7M288.1M302.5M
Gross Profit294.8M361.8M506.3M654.1M649.7M682.2M
Operating Income(192.8M)(397.9M)(374.9M)(439.9M)(349.4M)(331.9M)
Ebit(192.8M)(397.9M)(374.9M)(439.9M)(349.4M)(331.9M)
Ebitda(116.8M)(227.8M)(378.1M)(372.6M)(112.8M)(118.5M)
Income Before Tax(239.9M)(402.9M)(518.3M)(587.5M)(696.1M)(661.3M)
Net Income(251.6M)(438.2M)(523.9M)(559.0M)(626.6M)(595.3M)
Income Tax Expense11.7M35.2M5.6M(28.5M)(69.5M)(66.0M)
Tax Provision11.7M35.2M5.6M(28.5M)(87.1M)(82.7M)
Net Interest Income(12.5M)(56.4M)(86.0M)(90.9M)(109.4M)(103.9M)

PTC Therapeutics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of PTC Therapeutics. It measures of how well PTC is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money PTC Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money PTC had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what PTC Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Capital Expenditures45.4M56.0M85.3M152.5M120.6M126.6M
End Period Cash Flow295.5M216.3M197.2M295.9M594.0M623.7M
Change In Cash126.0M(79.2M)(19.1M)98.7M314.2M329.9M
Free Cash Flow(144.1M)(250.0M)(336.7M)(509.1M)(279.0M)(265.1M)
Depreciation32.2M84.9M64.1M128.8M236.6M248.4M
Other Non Cash Items49.4M46.1M128.3M82.8M151.3M158.9M
Net Income(251.6M)(438.2M)(523.9M)(559.0M)(626.6M)(595.3M)
Change To Inventory(3.5M)1.8M1.8M(6.7M)(8.2M)(7.8M)
Investments(341.8M)(505.6M)304.5M442.6M(49.9M)(47.4M)
Change Receivables11.5M(10.5M)(45.0M)(48.5M)(43.6M)(41.4M)
Change To Netincome97.8M65.1M230.4M113.8M130.8M79.0M

PTC Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining PTC Therapeutics's current stock value. Our valuation model uses many indicators to compare PTC Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PTC Therapeutics competition to find correlations between indicators driving PTC Therapeutics's intrinsic value. More Info.
PTC Therapeutics is regarded third in gross profit category among related companies. It is regarded third in cash flow from operations category among related companies . At this time, PTC Therapeutics' Gross Profit is comparatively stable compared to the past year.. Comparative valuation analysis is a catch-all model that can be used if you cannot value PTC Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for PTC Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PTC Therapeutics' earnings, one of the primary drivers of an investment's value.

PTC Therapeutics Systematic Risk

PTC Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PTC Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on PTC Therapeutics correlated with the market. If Beta is less than 0 PTC Therapeutics generally moves in the opposite direction as compared to the market. If PTC Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PTC Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PTC Therapeutics is generally in the same direction as the market. If Beta > 1 PTC Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.

About PTC Therapeutics Financials

What exactly are PTC Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include PTC Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential PTC Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may use each financial statement separately, they are all related. The changes in PTC Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on PTC Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze PTC Therapeutics Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as PTC Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of PTC has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if PTC Therapeutics' financials are consistent with your investment objective using the following steps:
  • Review PTC Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand PTC Therapeutics' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare PTC Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if PTC Therapeutics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

PTC Therapeutics Thematic Clasifications

PTC Therapeutics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
Cancer FightersView
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in PTC Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PTC Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of PTC Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.42)

At this time, PTC Therapeutics' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

PTC Therapeutics March 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of PTC Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PTC Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of PTC Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing PTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PTC Therapeutics's daily price indicators and compare them against related drivers.
When determining whether PTC Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if PTC Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ptc Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Ptc Therapeutics Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.
Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for PTC Stock analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.37)
Revenue Per Share
12.531
Quarterly Revenue Growth
0.834
Return On Assets
(0.12)
Return On Equity
(77.40)
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.